{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:20:07Z","timestamp":1791919207117,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004286","name":"Santen","doi-asserted-by":"publisher","award":["Investigator-initiated study grant"],"award-info":[{"award-number":["Investigator-initiated study grant"]}],"id":[{"id":"10.13039\/501100004286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40123-024-00906-1","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T15:03:47Z","timestamp":1709737427000},"page":"1197-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Short-Term Efficacy of Ophthalmic Cyclosporine: A 0.1% Cationic Emulsion in Dry Eye Patients Assessed Under Controlled Environment"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04492878","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3992-991X","authenticated-orcid":false,"given":"Laura","family":"Valencia-Nieto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8179-9253","authenticated-orcid":false,"given":"Jos\u00e9","family":"Pinto-Fraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7054-3287","authenticated-orcid":false,"given":"Marta","family":"Blanco-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5077-4448","authenticated-orcid":false,"given":"Itziar","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9429-1571","authenticated-orcid":false,"given":"Alberto","family":"L\u00f3pez-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9281-6255","authenticated-orcid":false,"given":"Carmen","family":"Garc\u00eda-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3673-0585","authenticated-orcid":false,"given":"Mar\u00eda J.","family":"Gonz\u00e1lez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-7796","authenticated-orcid":false,"given":"Amalia","family":"Enr\u00edquez-de-Salamanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8178-4836","authenticated-orcid":false,"given":"Margarita","family":"Calonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"906_CR1","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jtos.2017.08.003","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15:802\u201312.","journal-title":"Ocul Surf"},{"key":"906_CR2","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ajo.2014.01.001","volume":"157","author":"A L\u00f3pez-Miguel","year":"2014","unstructured":"L\u00f3pez-Miguel A, Tes\u00f3n M, Mart\u00edn-Monta\u00f1ez V, et al. Dry eye exacerbation in patients exposed to desiccating stress under controlled environmental conditions. Am J Ophthalmol. 2014;157:788\u201398.","journal-title":"Am J Ophthalmol"},{"key":"906_CR3","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/ICO.0000000000000960","volume":"35","author":"V Mart\u00edn-Monta\u00f1ez","year":"2016","unstructured":"Mart\u00edn-Monta\u00f1ez V, Enr\u00edquez-de-Salamanca A, L\u00f3pez-De La Rosa A, et al. Effect of environmental conditions on the concentration of tear inflammatory mediators during contact lens wear. Cornea. 2016;35:1192\u20138.","journal-title":"Cornea"},{"key":"906_CR4","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1159\/000066183","volume":"216","author":"SK Gupta","year":"2002","unstructured":"Gupta SK, Gupta V, Joshi S, Tandon R. Subclinically dry eyes in urban Delhi: an impact of air pollution? Ophthalmologica. 2002;216:368\u201371.","journal-title":"Ophthalmologica"},{"key":"906_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/aos.12985","volume":"94","author":"G Van Setten","year":"2016","unstructured":"Van Setten G, Labetoulle M, Baudouin C, Rolando M. Evidence of seasonality and effects of psychrometry in dry eye disease. Acta Ophthalmol. 2016;94:499\u2013506.","journal-title":"Acta Ophthalmol"},{"key":"906_CR6","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1167\/iovs.12-11361","volume":"54","author":"M Tes\u00f3n","year":"2013","unstructured":"Tes\u00f3n M, Gonz\u00e1lez-Garc\u00eda MJ, L\u00f3pez-Miguel A, et al. Influence of a controlled environment simulating an in-flight airplane cabin on dry eye disease. Invest Ophthalmol Vis Sci. 2013;54:2093\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"906_CR7","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1097\/OPX.0b013e31826f32e0","volume":"89","author":"SY Lee","year":"2012","unstructured":"Lee SY, Tong L. Lipid-containing lubricants for dry eye: a systematic review. Optom Vis Sci. 2012;89:1654\u201361.","journal-title":"Optom Vis Sci"},{"key":"906_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ajo.2004.04.052","volume":"138","author":"SC Pflugfelder","year":"2004","unstructured":"Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444\u201357.","journal-title":"Am J Ophthalmol."},{"key":"906_CR9","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0161-6420(99)90171-9","volume":"106","author":"P Marsh","year":"1999","unstructured":"Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sj\u00f6gren syndrome. Ophthalmology. 1999;106:811\u20136.","journal-title":"Ophthalmology"},{"key":"906_CR10","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/j.ophtha.2005.05.013","volume":"112","author":"LD Barber","year":"2005","unstructured":"Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005;112:1790\u20134.","journal-title":"Ophthalmology"},{"key":"906_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","volume":"47","author":"S Matsuda","year":"2000","unstructured":"Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47:119\u201325.","journal-title":"Immunopharmacology"},{"key":"906_CR12","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1001\/archopht.118.11.1489","volume":"118","author":"KS Kunert","year":"2000","unstructured":"Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118:1489\u201396.","journal-title":"Arch Ophthalmol"},{"key":"906_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/00003226-200007000-00018","volume":"19","author":"K Turner","year":"2000","unstructured":"Turner K, Pflugfelder SC, Ji Z, Feuer WJ, Stern M, Reis BL. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea. 2000;19:492\u20136.","journal-title":"Cornea"},{"key":"906_CR14","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/bjo.2008.150011","volume":"94","author":"L Baiza-Duran","year":"2010","unstructured":"Baiza-Duran L, Medrano-Palafox J, Hernandez-Quintela E, Lozano-Alcazar J, Alaniz-de la OJ. A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome. Br J Ophthalmol. 2010;94:1312\u20135.","journal-title":"Br J Ophthalmol"},{"key":"906_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","volume":"107","author":"K Sall","year":"2000","unstructured":"Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107:631\u20139.","journal-title":"Ophthalmology"},{"key":"906_CR16","doi-asserted-by":"publisher","first-page":"1336043","DOI":"10.1080\/20016689.2017.1336043","volume":"5","author":"YI Eroglu","year":"2017","unstructured":"Eroglu YI. A comparative review of Haute Autorit\u00e9 de Sant\u00e9 and National Institute for health and care excellence health technology assessments of Ikervis\u00ae to treat severe keratitis in adult patients with dry eye disease which has not improved despite treatment with tear substitutes. J Mark Access Health Policy. 2017;5:1336043.","journal-title":"J Mark Access Health Policy"},{"key":"906_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5301\/ejo.5000779","volume":"26","author":"A Leonardi","year":"2016","unstructured":"Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26:287\u201396.","journal-title":"Eur J Ophthalmol"},{"key":"906_CR18","doi-asserted-by":"publisher","first-page":"520","DOI":"10.5301\/ejo.5000952","volume":"27","author":"C Baudouin","year":"2017","unstructured":"Baudouin C, Figueiredo FC, Messmer EM, et al. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol. 2017;27:520\u201330.","journal-title":"Eur J Ophthalmol."},{"key":"906_CR19","doi-asserted-by":"publisher","first-page":"678","DOI":"10.5301\/ejo.5001002","volume":"27","author":"C Baudouin","year":"2017","unstructured":"Baudouin C, de la Maza MS, Amrane M, et al. One-Year Efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. 2017;27:678\u201385.","journal-title":"Eur J Ophthalmol."},{"key":"906_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/OPTH.S150957","volume":"12","author":"PJ Pisella","year":"2018","unstructured":"Pisella PJ, Labetoulle M, Doan S, et al. Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program. Clin Ophthalmol. 2018;12:289\u201399.","journal-title":"Clin Ophthalmol."},{"key":"906_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clae.2009.12.010","volume":"33","author":"RL Chalmers","year":"2010","unstructured":"Chalmers RL, Begley CG, Caffery B. Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): discimination across self-assessed severity and aqueous tear deficient dry eye diagnosis. Cont Lens Anterior Eye. 2010;33:55\u201360.","journal-title":"Cont Lens Anterior Eye"},{"key":"906_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S1542-0124(12)70053-8","volume":"5","author":"DA Schaumberg","year":"2007","unstructured":"Schaumberg DA, Gulati A, Mathers WD, et al. Development and validation of a short global dry eye symptom index. Ocul Surf. 2007;5:50\u20137.","journal-title":"Ocul Surf"},{"key":"906_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/ICL.0000000000000693","volume":"47","author":"J Pinto-Fraga","year":"2021","unstructured":"Pinto-Fraga J, Calonge M, Enr\u00edquez-de-Salamanca A, Fern\u00e1ndez I, Gonz\u00e1lez-Garc\u00eda MJ, Steven P. Development of a questionnaire for detecting changes in dry eye disease-related symptoms. Eye Contact Lens. 2021;47:8\u201314.","journal-title":"Eye Contact Lens"},{"key":"906_CR24","first-page":"989","volume":"62","author":"RC Aitken","year":"1969","unstructured":"Aitken RC. Measurement of feelings using visual analogue scales. Proc R Soc Med. 1969;62:989\u201393.","journal-title":"Proc R Soc Med"},{"key":"906_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/00006324-199303000-00011","volume":"70","author":"RL Terry","year":"1993","unstructured":"Terry RL, Schnider CM, Holden BA, et al. CCLRU standards for success of daily and extended wear contact lenses. Optom Vis Sci. 1993;70:234\u201343.","journal-title":"Optom Vis Sci"},{"key":"906_CR26","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","volume":"22","author":"AJ Bron","year":"2003","unstructured":"Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22:640\u201350.","journal-title":"Cornea"},{"key":"906_CR27","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1167\/iovs.10-6997f","volume":"52","author":"A Tomlinson","year":"2011","unstructured":"Tomlinson A, Bron AJ, Korb DR, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011;52:2006\u201349.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"906_CR28","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1167\/iovs.10-6997g","volume":"52","author":"G Geerling","year":"2011","unstructured":"Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52:2050\u201364.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"906_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15:575\u2013628.","journal-title":"Ocul Surf"},{"key":"906_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ophtha.2015.09.029","volume":"123","author":"J Pinto-Fraga","year":"2016","unstructured":"Pinto-Fraga J, L\u00f3pez-Miguel A, Gonz\u00e1lez-Garc\u00eda MJ, et al. Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial. Ophthalmology. 2016;123:141\u201353.","journal-title":"Ophthalmology"},{"key":"906_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jtos.2014.12.006","volume":"13","author":"KH Wan","year":"2015","unstructured":"Wan KH, Chen LJ, Young AL. Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysis. Ocul Surf. 2015;13:213\u201325.","journal-title":"Ocul Surf."},{"key":"906_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108294","volume":"201","author":"VL Perez","year":"2020","unstructured":"Perez VL, Stern ME, Pflugfelder SC. Inflammatory basis for dry eye disease flares. Exp Eye Res. 2020;201: 108294.","journal-title":"Exp Eye Res"},{"key":"906_CR33","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/OPX.0000000000000673","volume":"92","author":"M Tes\u00f3n","year":"2015","unstructured":"Tes\u00f3n M, L\u00f3pez-Miguel A, Neves H, Calonge M, Gonz\u00e1lez-Garc\u00eda MJ, Gonz\u00e1lez-M\u00e9ijome JM. Influence of climate on clinical diagnostic dry eye tests: pilot study. Optom Vis Sci. 2015;92:284\u20139.","journal-title":"Optom Vis Sci"},{"key":"906_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","volume":"15","author":"JS Wolffsohn","year":"2017","unstructured":"Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15:539\u201374.","journal-title":"Ocul Surf"},{"key":"906_CR35","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2147\/OPTH.S258081","volume":"14","author":"P Fogagnolo","year":"2020","unstructured":"Fogagnolo P, Quisisana C, Caretti A, et al. Efficacy and safety of VisuEvo\u00ae and Cationorm\u00ae for the treatment of evaporative and non-evaporative dry eye disease: a multicenter, double-blind, cross-over, randomized clinical trial. Clin Ophthalmol. 2020;14:1651\u201363.","journal-title":"Clin Ophthalmol"},{"key":"906_CR36","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s40123-022-00487-x","volume":"11","author":"G Geerling","year":"2022","unstructured":"Geerling G, Hamada S, Trocm\u00e9 S, et al. Real-world effectiveness, tolerability and safety of cyclosporine a 0.1% cationic emulsion in severe keratitis and dry eye treatment. Ophthalmol Ther. 2022;11:1101\u20137.","journal-title":"Ophthalmol Ther."},{"key":"906_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/bjophthalmol-2017-311801","volume":"103","author":"A Leonardi","year":"2019","unstructured":"Leonardi A, Messmer EM, Labetoulle M, et al. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. Br J Ophthalmol. 2019;103:125\u201331.","journal-title":"Br J Ophthalmol."},{"key":"906_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/IIO.0000000000000168","volume":"57","author":"M Calonge","year":"2017","unstructured":"Calonge M, Pinto-Fraga J, Gonz\u00e1lez-Garc\u00eda MJ, et al. Effects of the external environment on dry eye disease. Int Ophthalmol Clin. 2017;57:23\u201340.","journal-title":"Int Ophthalmol Clin"},{"key":"906_CR39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ajo.2015.04.008","volume":"160","author":"QL Moore","year":"2015","unstructured":"Moore QL, De Paiva CS, Pflugfelder SC. Effects of dry eye therapies on environmentally induced ocular surface disease. Am J Ophthalmol. 2015;160:135\u201342.","journal-title":"Am J Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-00906-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-024-00906-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-00906-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T18:54:02Z","timestamp":1713898442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-024-00906-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1007\/s40123-024-00906-1","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]},"assertion":[{"value":"11 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicting relationship exists for any author. Disclosures of Dr. Margarita Calonge are the following: Research\/clinical trials contracts, consultantships,advisory boards and\/or lectures for Novartis, Santen Pharmaceutical, Johnson & Johnson, Horus Pharma, Fidia Farmaceutica, UrsaPharm GmbH, and Thea Laboratories. Alberto Lopez Miguel is an Editorial Board member of Ophthalmology and Therapy. Alberto Lopez Miguel was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. The remaining authors have no relationship to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The Ethics Committee of the Valladolid University Clinical Hospital (Valladolid, Spain) and the Spanish Drugs and Health Products Administration () (EudraCT number: 2019-000982-19) approved the trial. It was registered at the US National Institutes of Health (ClinicalTrials.gov, ID: NCT04492878). It was conducted at the Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain. The study followed the tenets of the Declaration of Helsinki and the Good Clinical Practices.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}